Unique Funny Recommendations On Oxymatrine
1% (n?=?48?471) received ��90 DDDs within the index period of 1?year (compatible with medication for one quarter). Most patients received ��30 DDDs (absolute 33.3%) or >30 & ��60 DDDs (absolute 26.2%); 0.6% of patients (n?=?445) received between 331 and 360 DDDs compatible with a 12-month supply (Fig.?3). Defined daily doses used for the calculation can be found in Table?1. A total of 13?822 patients received any prescription of LABAs (median age 61?years, 54.9% female) for a median duration of 90?days. For reference see Tables?2 and 3. As many as 55.6% of these patients (n?=?7680) received ��90 DDDs only; 23.3% had medication for only 1?month, 20.0% for 2?months and 3.7% (n?=?506) received DDDs for 12?months (Fig.?3). Patients who used both ICS and LABAs (free combination) usually received similar DDD quantities with 21.0% (n?=?1483) Pomalidomide ic50 receiving more LABAs than ICS. Some 1.8% (n?=?126) selleck products even received three times more DDDs of LABA than ICS. Of patients receiving fixed dose combinations of LABA and ICS, 53.5% (n?=?56?185) received medication for 90?days only, 15.8% received medication for a maximum of 30?days (n?=?16?593), 23.5% (n?=?24?679) for 31�C60?days and 2.1% of (2205) patients received medication sufficient for 1?year (Fig.?3). The median supply lasted 90?days. Pharmacotherapy of patients with short-acting ��2-agonists? A total of 1?33?206 patients (27.6%) received SABA as a quick reliever for a median duration of 50?days, 72.3% (n?=?96?674) had DDDs for 3?months, 45.0% (n?=?59?986) were supplied with medication for 30?days and 20.6% (n?=?27?499) for 31�C60?days and 0.7% of patients (n?=?8272) had enough medication for 1?year (330�C360 DDDs). Of note, 8272 patients (6.2%) received more than 360 DDDs of SABA (Fig.?3). The subgroup comprised 3601 patients. According to the medication prescribed, 1176 patients were classified as having stage 1, 653 stage 2, 1574 stage 3 and 198 stage 4 asthma. Most patients received medication for a maximum of 90?days, which was similar to the total group of patients (Tables?2 and 3). Patients who used both ICS and LABA (in a free combination) usually received similar DDD quantities. This was analyzed in patients with stage 3 asthma [quantity of stage 4 patients was not sufficient to be analyzed (n?=?187)]. The scatterplot in Fig.?4 illustrates that most patients Oxymatrine received
